

Fatty acid dietary supplement for chronic low back pain

Submission date 26/04/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/04/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 18/08/2023	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Approximately 8 out of 10 people worldwide will suffer from low back pain at some point in their life. Most of the episodes of low back pain resolve spontaneously, however, the subset of patients who continue to experience chronic symptoms is so large that it has been acknowledged as the most common cause of disability. Medical treatment for chronic low back pain consists of long-term use of anti-inflammatories and pain killers, that when used for long periods of time can cause severe adverse effects, injuring the stomach, liver, and kidneys. Cetylated fatty acids are a dietary supplement that has showed to decrease pain related to knee osteoarthritis as well as inflammatory markers in vitro. They are safe and rarely cause adverse effects when ingested for a long time. But there is no information regarding the effectiveness of cetylated fatty acids in improving pain and function related to low back pain. Therefore we have decided to conduct a pilot study to evaluate this.

The aim of this study is to evaluate the effectiveness of Cetylated Fatty Acids in reducing pain and improving function in patients with chronic lower back pain.

Who can participate?

Patients, both male and female, age 21 or older, suffering from low back pain for more than 3 months can participate in the study.

What does the study involve?

The study involves taking a dietary supplement that consists of Cetylated Fatty Acids for 1 month. Patients that participate in the study are going to be evaluated for pain and function using validated questionnaires, before starting the treatment and at the end of the month. Any adverse effects related to the dietary supplement are going to be evaluated and treated (if necessary) during the whole follow-up

What are the possible benefits and risks of participating?

The probable benefits of the dietary supplement are improving low back pain and decreasing disability related to the pain.

Risks of participating are rare, however, adverse effects related to the dietary supplement may occur. Some of these adverse effects may be allergic reactions, heartburn, nausea, vomiting, and diarrhea.

Where is the study run from?

The private practice of Dr Vijay B. Vad, New York City, NY, USA.

When is the study starting and how long is it expected to run for?

April 2022 to July 2022

Who is funding the study?

The Vad foundation, New York, NY, USA.

Who is the main contact?

Dr Antonio Madrazo-Ibarra, amadrazoi@live.com

Contact information

Type(s)

Principal Investigator

Contact name

Dr Vijay Vad

ORCID ID

<http://orcid.org/0000-0002-5167-6241>

Contact details

519 E 72nd St Suite 203

New York

United States of America

10021

+1 212 606 1306

vadv@hss.edu

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

The effectiveness of cetylated fatty acids on pain and mobility in patients with chronic low back pain

Study objectives

A dietary supplement based on cetyl fatty acids will decrease pain and increase function in patients with chronic low back pain.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 02/28/2022, WCG Institutional Review Board (1019 39th Ave., SE, Suite 120, Puyallup, WA 98374; +1 855-818-2289; clientservices@wcgirb.com), ref: 20220202, study number: 13291166

Study design

Prospective interventional cohort study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Home

Study type(s)

Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Low back pain

Interventions

Patients with chronic low back pain will take 2 capsules twice a day of LipoCet (Cetylated Fatty Acids) 300mg for 1 month.

Intervention Type

Supplement

Primary outcome measure

Patients' functionality based on the Oswestry Low Back Pain Disability Questionnaire (ODI) evaluated pre-treatment and after 1 month of initiating the dietary supplement.

Secondary outcome measures

1. Low back pain based on the Numeric Pain Rating Scale (0-10) evaluated pre-treatment and after 1 month of initiating the dietary supplement.
2. Adverse effects related to the dietary supplement evaluated after 1 month of the treatment using a questionnaire.

Overall study start date

27/04/2022

Completion date

30/07/2022

Eligibility

Key inclusion criteria

Patients over 21 years of age with low back pain for more than 3 months.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

35

Key exclusion criteria

1. Patients currently on narcotic pain medication
2. Patients unwilling to follow the study protocol
3. Pregnant or currently breastfeeding
4. Patients with low back pain from a traumatic injury
5. Patients currently using a pain patch (e.g. lidocaine)

Date of first enrolment

01/05/2022

Date of final enrolment

30/06/2022

Locations

Countries of recruitment

United States of America

Study participating centre

Private practice of Dr. Vijay B. Vad
519 E 72nd St Suite 203
New York City
United States of America
10021

Sponsor information

Organisation

Vad Foundation

Sponsor details

220 E 65th Street
New York
United States of America
10065-6620
+1 212 606 1306
vadv@hss.edu

Sponsor type

Charity

Website

<http://www.nonprofitfacts.com/NY/Vad-Foundation.html#ixzz7DdLpHLeT>

Funder(s)

Funder type

Charity

Funder Name

Vad Foundation

Results and Publications

Publication and dissemination plan

The results of this study will be published in a medical journal.

Intention to publish date

01/12/2022

Individual participant data (IPD) sharing plan

Raw data (coded to avoid identification of patients) will be shared with anyone upon request to the primary investigator.

vadv@hss.edu

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		28/02/2023	18/08/2023	Yes	No